A Diverse and Experienced Board
Next Science's Board of Directors has extensive governance and operating experience. Collectively they have decades of experience in the life sciences industry with a focus on novel technology commercialization. Working closely with the Leadership Team they are focused on driving Next Science forward and bringing Next Science's novel Xbio™ technology to market.
Chairman and Non-Executive Director
Bruce Hancox joined the board in April 2012. Mr. Hancox is currently a director of a number of listed and private Australian and New Zealand companies. He previously held a number of senior roles at Brierley Investments Ltd. in New Zealand as General Manager, Group CEO and Chairman, as well as serving on the board of a number of their subsidiaries.
Director and Next Science CEO
Judith Mitchell joined Next Science as CEO in August 2017. Previously Ms. Mitchell was President, DePuy Synthes Asia Pacific, the Orthopedics Division of J&J, holding the same role at Synthes GmbH prior to acquisition. Prior to that, Ms. Mitchell held various executive management roles at Cochlear and GE.
Dan Spira joined the board in June 2017. Mr. Spira is the CEO of iNova Pharmaceuticals. Previously Vice President at Valeant Pharmaceuticals / Bausch + Lomb from 2011 to 2015. Prior to Valeant, Mr. Spira spent over 15 years at J&J progressing through a range of sales, marketing and general management roles.